Clinical Trials Logo

Filter by:
NCT ID: NCT05939947 Recruiting - Liver Cirrhosis Clinical Trials

A Clinical Trial of ALE.F02 in Patients With Advanced Liver Fibrosis and/or With Mild Cirrhosis

FEGATO-01
Start date: April 1, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate how a human body processes ALE.F02 (pharmacokinetics profile) in patients with impaired liver function.

NCT ID: NCT05937295 Recruiting - Clinical trials for Fibrolamellar Hepatocellular Carcinoma

FusionVAC22_01: Fusion Transcript-based Peptide Vaccine Combined With Immune Checkpoint Inhibition

FusionVAC22
Start date: September 26, 2023
Phase: Phase 1
Study type: Interventional

The aim of this clinical trial is to evaluate the immunogenicity along with safety and toxicity as well as first efficacy of a DNAJB1-PRKACA fusion transcript-based peptide vaccine (Fusion-VAC-XS15) in combination with anti-programmed cell death-ligand 1 immune checkpoint inhibition (ICI) by Atezolizumab (TecentriqTM) in patients with Fibrolamellar hepatocellular carcinoma (FL-HCC) or other cancer entities carrying the DNAJB1-PRKACA fusion transcript.

NCT ID: NCT05936684 Recruiting - Quality of Life Clinical Trials

Breathing and Decision-Making

ProlEx-MRI
Start date: July 4, 2023
Phase: N/A
Study type: Interventional

The study aims to investigate how slow breathing with prolonged exhalation (i.e., ProlEx breathing) modulates decision-making under risk in healthy participants. To do this, a short-term breathing intervention is combined with a decision-making paradigm while neural, physiological, and behavioral data are recorded.

NCT ID: NCT05936567 Recruiting - Clinical trials for Chronic Spontaneous Urticaria

Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria

Start date: July 31, 2023
Phase: Phase 2
Study type: Interventional

This study is being conducted to evaluate the efficacy and safety of povorcitinib in adults with CSU that is inadequately controlled using SOC treatments.

NCT ID: NCT05936359 Recruiting - Clinical trials for Myeloproliferative Neoplasms

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

Start date: September 25, 2023
Phase: Phase 1
Study type: Interventional

This study is being conducted to evaluate the safety, tolerability, and dose-limiting toxicity (DLT) and determine the maximum tolerated dose (MTD) and/or recommended dose(s) for expansion (RDE) of INCA033989 administered as a monotherapy or in combination with ruxolitinib in participants with myeloproliferative neoplasms.

NCT ID: NCT05935865 Recruiting - Clinical trials for Pulmonary Hypertension

Monitoring of the Influence of Approved PH-therapies RV-PA Coupling

Start date: February 13, 2023
Phase:
Study type: Observational

The goal of this observational study is to learn about the acute (days) changes in right ventricular functions caused by initiation of pharmacological therapies in patients with precapillary pulmonary hypertension. The main question it aims to answer is: • Course of afterload and intrinsic contractility throughout the hospital stay Participants will be equipped with a device for continuous monitoring and recording of the right ventricular pressure signal.

NCT ID: NCT05934526 Recruiting - Clinical trials for Pulmonary Arterial Hypertension

Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)

Start date: December 28, 2023
Phase: Phase 3
Study type: Interventional

The primary objective of the study is to determine the effect of seralutinib on improving exercise capacity in subjects with WHO Group 1 PAH who are FC II or III. The secondary objective for this trial is to determine time to clinical worsening.

NCT ID: NCT05934032 Recruiting - Clinical trials for Carcinoma, Non-Small-Cell Lung

National Network Genomic Medicine Lung Cancer, Germany

nNGM
Start date: April 1, 2018
Phase:
Study type: Observational [Patient Registry]

Registry of the national Network Genomic Medicine Lung Cancer (nNGM), linking data on molecular diagnostics, clinical characteristics, treatment patterns and outcomes of subjects with non-small cell lung cancer (NSCLC) from 23 specialized cancer centres and more than 400 general hospitals and oncological practices in Germany

NCT ID: NCT05933577 Recruiting - Melanoma Clinical Trials

A Clinical Study of V940 Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)

Start date: July 19, 2023
Phase: Phase 3
Study type: Interventional

The purpose of this study is to learn if V940 which is an individualized neoantigen therapy (INT; formerly, called messenger ribonucleic acid [mRNA]-4157) with pembrolizumab (MK-3475) is safe and prevents cancer from returning in people with high-risk melanoma. Researchers want to know if V940 with pembrolizumab is better than receiving pembrolizumab alone at preventing the cancer from returning.

NCT ID: NCT05933200 Recruiting - Clinical trials for Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)

A Study to Determine the Effect of Triheptanoin Compared With Even-chain, MCT on MCEs in Pediatric Patients With LC-FAOD

Start date: February 28, 2023
Phase: Phase 3
Study type: Interventional

The main goal of this study is to evaluate the effects of triheptanoin versus Medium-chain Triglycerides (MCT) on frequency of Major Clinical Events (MCEs).